BioNTech share: It will be another very exciting week!

This week, the focus will once again be on the BioNTech share. In the European Union, BioNTech’s COVID-19 vaccine BNT162 is expected to be approved, which the Mainz-based company and US pharmaceutical company Pfizer brought to market in record time. The current news about mutations of the SARS-CoV-2 virus make approval anything but unlikely, especially since the vaccine should also be effective against mutated versions of the pathogen.

In terms of charts, the BioNTech share is undergoing a potential stabilization after its recent downward movement from the all-time high of $ 131 on Thursday, reaching $ 101.62. The 50-day line at currently $ 101.91, which offered the stabilization zone for BioNTech’s share price for three trading days in a row, is helpful here. On the other hand, the question of how much of the good news about BioNTech is already included in the course remains extremely interesting.

Related Articles

Back to top button